Advanced search
Publication Cover
Pain Management Volume 2, 2012 - Issue 4
Submit an article Journal homepage
95
Views
0
CrossRef citations to date
0
Altmetric
Review

Overview of Migraine Treatment

Mari Bozoghlanian1 University of California, Irvine Medical Center, Department of Radiology, 101 The City Drive, Building 1, Room 0115, Orange, CA92868, USA.Correspondence[email protected]
&
Sridhar V Vasudevan2 Wisconsin Rehabilitation Medicine Professionals, S.C., PO Box 240860, Milwaukee, WI53224, USA
Pages 399-414 | Published online: 02 Aug 2012

References

  • Johnston MM , RapoportAM. Triptans for the management of migraine. Drugs70(12) , 1505–1518 (2010).
  • Stewart WF , WoodC, ReedML, RoyJ, LiptonRB, GroupAA. Cumulative lifetime migraine incidence in women and men. Cephalalgia28(11) , 1170–1178 (2008).
  • Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia24(Suppl. 1) , 1–160 (2004).
  • Burton WN , LandySH, DownsKE, RunkenMC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin. Proc.84(5) , 436–445 (2009).
  • Silberstein S , LoderE, DiamondS et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia 27(3) , 220–234 (2007).
  • Bigal ME , KrymchantowskiAV, HoT. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq. Neuropsiquiatr.67(2B) , 559–569 (2009).
  • Bozoghlanian M , VasudevanS. Migraine Pathophysiology. Pain Manage.1(4) , 337–352 (2011).
  • Eikermann-Haerter K , AyataC. Cortical spreading depression and migraine. Curr. Neurol. Neurosci. Rep.10(3) , 167–173 (2010).
  • Sprenger T , GoadsbyPJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Med.7 , 71 (2009).
  • Tfelt-Hansen P , BlockG, DahlöfC et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20(9) , 765–786 (2000).
  • Khoury CK , CouchJR. Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des. Devel. Ther.4 , 9–17 (2010).
  • Lipton RB , StewartWF, StoneAM, LáinezMJ, Sawyer JP; Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) study: a randomized trial. JAMA284(20) , 2599–2605 (2000).
  • Evers S , AfraJ, FreseA et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur. J. Neurol. 16(9) , 968–981 (2009).
  • Aurora SK , DodickDW, TurkelCC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7) , 793–803 (2010).
  • Moloney MF , Cranwell-BruceLA. Pharmacological management of migraine headaches. Nurse Pract.35(9) , 16–22; quiz 23 (2010).
  • Silberstein SD . Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55(6) , 754–762 (2000).
  • Diener HC , PfaffenrathV, PagelerL, PeilH, AicherB. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia25(10) , 776–787 (2005).
  • Goldstein J , SilbersteinSD, SaperJR, RyanRE, LiptonRB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache46(3) , 444–453 (2006).
  • Silberstein SD , FreitagFG, RozenTD et al. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache 45(10) , 1317–1327 (2005).
  • Tulunay FC , ErgünH, GülmezSE et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. Funct. Neurol. 19(3) , 197–202 (2004).
  • Göbel H , HeinzeA, NiederbergerU, WittT, ZumbroichV. Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study. Cephalalgia24(10) , 888–893 (2004).
  • Myllylä VV , HavankaH, HerralaL et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 38(3) , 201–207 (1998).
  • Ellis GL , DelaneyJ, DeHartDA, OwensA. The efficacy of metoclopramide in the treatment of migraine headache. Ann. Emerg. Med.22(2) , 191–195 (1993).
  • Friedman BW , CorboJ, LiptonRB et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 64(3) , 463–468 (2005).
  • Tfelt-Hansen PC , KoehlerPJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia28(8) , 877–886 (2008).
  • Monteith TS , GoadsbyPJ. Acute migraine therapy: new drugs and new approaches. Curr. Treat. Options Neurol.13(1) , 1–14 (2011).
  • Panconesi A , AnselmiB, CurradiC, PerfettoF, PilusoA, FranchiG. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache34(4) , 194–197 (1994).
  • Láinez MJ , GalvánJ, HerasJ, VilaC. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol.14(3) , 269–275 (2007).
  • Diener HC , JansenJP, RechesA et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur. Neurol. 47(2) , 99–107 (2002).
  • Christie S , GöbelH, MateosV et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur. Neurol. 49(1) , 20–29 (2003).
  • Tfelt-Hansen P . Ergotamine, dihydroergotamine: current uses and problems. Curr. Med. Res. Opin.17(Suppl. 1) , S30–S34 (2001).
  • Silberstein SD , YoungWB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology45(3 Pt 1) , 577–584 (1995).
  • Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology45(3 Pt 1) , 585–587 (1995).
  • Tfelt-Hansen P , SaxenaPR, DahlöfC et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123(Pt 1) , 9–18 (2000).
  • Saper JR , SilbersteinS. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache46(Suppl. 4) , S171–S181 (2006).
  • Silberstein SD , KoriSH, TepperSJ et al. Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine. Presented at: 14th Congress of International Headache Society. Philadelphia, PA, USA, 10–13 September 2009.
  • Evers S , GralowI, BauerB et al. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin. Neuropharmacol. 22(4) , 201–206 (1999).
  • Humphrey PP , FeniukW. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci.12(12) , 444–446 (1991).
  • Humphrey PP , FeniukW, MarriottAS, TannerRJ, JacksonMR, TuckerML. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol.31(5) , 282–290 (1991).
  • Cutrer FM , CharlesA. The neurogenic basis of migraine. Headache48(9) , 1411–1414 (2008).
  • Olesen J , BursteinR, AshinaM, Tfelt-HansenP. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol.8(7) , 679–690 (2009).
  • Ferrari MD , GoadsbyPJ, RoonKI, LiptonRB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22(8) , 633–658 (2002).
  • Pascual J , MateosV, RoigC, Sanchez-Del-RioM, JiménezD. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache47(8) , 1152–1168 (2007).
  • Silberstein SD . Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics7(2) , 153–158 (2010).
  • Brandes JL , CadyRK, FreitagFG et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 49(10) , 1435–1444 (2009).
  • Farr SJ , LinnL, ShabeP, NewmanE, ChandlerP. Pharmacokinetics, bioequivalence, and safety of the sumatriptan DosePro needle-free system vs. IMITREX STATdose in healthy adults. Presented at: The 50th Annual Scientific Meeting of the American Headache Society. Boston, MA, USA, 28 June 2008.
  • Pierce M , MarburyT, O‘NeillC, SiegelS, DuW, SebreeT. Zelrix: a novel transdermal formulation of sumatriptan. Headache49(6) , 817–825 (2009).
  • Pierce MW . Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics7(2) , 159–163 (2010).
  • Goadsby PJ . The ‘Act when Mild‘ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia28(Suppl. 2) , 36–41 (2008).
  • Linde M , MellbergA, DahlöfC. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia26(2) , 113–121 (2006).
  • Olesen J , DienerHC, SchoenenJ, HettiarachchiJ. No effect of eletriptan administration during the aura phase of migraine. Eur. J. Neurol.11(10) , 671–677 (2004).
  • Bates D , AshfordE, DawsonR et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 44(9) , 1587–1592 (1994).
  • Ferrari MD , JamesMH, BatesD et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 14(5) , 330–338 (1994).
  • Diener HC , LimmrothV. Advances in pharmacological treatment of migraine. Expert Opin. Investig. Drugs10(10) , 1831–1845 (2001).
  • Bigal ME , BordiniCA, AntoniazziAL, SpecialiJG. The triptan formulations: a critical evaluation. Arq. Neuropsiquiatr.61(2A) , 313–320 (2003).
  • Brandes JL , KudrowD, StarkSR et al. Sumatriptan–naproxen for acute treatment of migraine: a randomized trial. JAMA 297(13) , 1443–1454 (2007).
  • Sclar DA , RobisonLM, SkaerTL. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. Headache48(1) , 126–129 (2008).
  • Soldin OP , Tonning JM; Obstetric–Fetal Pharmacology Research Unit Network. Serotonin syndrome associated with triptan monotherapy. N. Engl. J. Med.358(20) , 2185–2186 (2008).
  • Bigal ME , LiptonRB. Excessive opioid use and the development of chronic migraine. Pain142(3) , 179–182 (2009).
  • Moschiano F , D‘AmicoD, BussoneG. Migraine prophylaxis: key points for the practising clinician. Neurol. Sci.30(Suppl. 1) , S33–S37 (2009).
  • Fenstermacher N , LevinM, WardT. Pharmacological prevention of migraine. BMJ342 , d583 (2011).
  • Tepper SJ , D‘AmicoD, BaosV, BlakeboroughP, DowsonAJ. Guidelines for prescribing prophylactic medications for migraine: a survey among headache specialist physicians in different countries. Headache Care1(4) , 267–272 (2004).
  • Diamond S , BigalME, SilbersteinS, LoderE, ReedM, LiptonRB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache47(3) , 355–363 (2007).
  • Linde K , RossnagelK. Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev. (2) , CD003225 (2004).
  • Pringsheim T , DavenportWJ, BeckerWJ. Prophylaxis of migraine headache. CMAJ182(7) , E269–E276 (2010).
  • Wyszynski DF , NambisanM, SurveT et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64(6) , 961–965 (2005).
  • Fountain NB . A pregnant pause to consider teratogenicity of topiramate. Epilepsy Curr.9(2) , 36–38 (2009).
  • Mathew NT , RapoportA, SaperJ et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41(2) , 119–128 (2001).
  • Parsekyan D . Migraine prophylaxis in adult patients. West. J. Med.173(5) , 341–345 (2000).
  • Gray RN , GoslinRE, McCroryDC, EberleinK, TulskyJ, HasselbladV. Technical review 2.3: Drug treatments for the prevention of migraine. Prepared for the Agency for Health Care Policy and Research, MD, USA (1999).
  • Modi S , LowderDM. Medications for migraine prophylaxis. Am. Fam. Physician73(1) , 72–78 (2006).
  • Silberstein SD . Methysergide. Cephalalgia18(7) , 421–435 (1998).
  • Stark RJ , StarkCD. Migraine prophylaxis. Med. J. Aust.189(5) , 283–288 (2008).
  • Botulinum toxin for chronic migraine. Med. Lett. Drugs Ther.53(1356) , 7–8 (2011).
  • Marmura MJ , SilbersteinSD. Current understanding and treatment of headache disorders: five new things. Neurology76(7 Suppl. 2) , S31–S36 (2011).
  • Aoki KR . Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache43(Suppl. 1) , S9–S15 (2003).
  • Aoki KR . Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology26(5) , 785–793 (2005).
  • Silberstein S , MathewN, SaperJ, JenkinsS. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache40(6) , 445–450 (2000).
  • Mathew NT , FrishbergBM, GawelM et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45(4) , 293–307 (2005).
  • Magis D , SchoenenJ. Treatment of migraine: update on new therapies. Curr. Opin. Neurol.24(3) , 203–210 (2011).
  • Diener HC , DodickDW, AuroraSK et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7) , 804–814 (2010).
  • Schiapparelli P , AllaisG, Castagnoli Gabellari I, Rolando S, Terzi MG, Benedetto C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol. Sci.31(Suppl. 1) , S137–S139 (2010).
  • Agosti R , DukeRK, ChrubasikJE, ChrubasikS. Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review. Phytomedicine13(9–10) , 743–746 (2006).
  • Käufeler R , PolasekW, BrattströmA, KoetterU. Efficacy and safety of butterbur herbal extract Ze 339 in seasonal allergic rhinitis: postmarketing surveillance study. Adv. Ther.23(2) , 373–384 (2006).
  • Schoenen J , JacquyJ, LenaertsM. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology50(2) , 466–470 (1998).
  • Sándor PS , Di Clemente L, Coppola G et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology64(4) , 713–715 (2005).
  • Peikert A , WilimzigC, Köhne-VollandR. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia16(4) , 257–263 (1996).
  • Pittler MH , ErnstE. Feverfew for preventing migraine. Cochrane Database Syst. Rev. (1) , CD002286 (2004).
  • Owen JM , GreenBN. Homeopathic treatment of headaches: a systematic review of the literature. J. Chiropr. Med.3(2) , 45–52 (2004).
  • Grazzi L , AndrasikF. Non-pharmacological approaches in migraine prophylaxis: behavioral medicine. Neurol. Sci.31(Suppl. 1) , S133–S135 (2010).
  • Linde K , AllaisG, BrinkhausB, ManheimerE, VickersA, WhiteAR. Acupuncture for migraine prophylaxis. Cochrane Database Syst. Rev.1 , CD001218 (2009).
  • Lipton RB , PearlmanSH. Transcranial magnetic simulation in the treatment of migraine. Neurotherapeutics7(2) , 204–212 (2010).
  • Lipton RB , DodickDW, SilbersteinSD et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 9(4) , 373–380 (2010).
  • Mohamad Y , KothariR, HughesG. Transcranial magnetic stimulation (TMS) relieves migraine headache. Headache46 , 839 (2006).
  • Brighina F , PiazzaA, VitelloG et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J. Neurol. Sci. 227(1) , 67–71 (2004).
  • Teepker M , HötzelJ, TimmesfeldN et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 30(2) , 137–144 (2010).
  • Narin SO , PinarL, ErbasD, OztürkV, IdimanF. The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin. Rehabil.17(6) , 624–630 (2003).
  • Lockett DM , CampbellJF. The effects of aerobic exercise on migraine. Headache32(1) , 50–54 (1992).
  • Köseoglu E , AkboyrazA, SoyuerA, ErsoyAO. Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura. Cephalalgia23(10) , 972–976 (2003).
  • Varkey E , CiderA, CarlssonJ, LindeM. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia31(14) , 1428–1438 (2011).
  • Peterlin BL . Bariatric surgery in obese migraineurs: mounting evidence but important questions remain. Cephalalgia31(13) , 1333–1335 (2011).
  • Peterlin BL , RapoportAM, KurthT. Migraine and obesity: epidemiology, mechanisms, and implications. Headache50(4) , 631–648 (2010).
  • Peterlin BL , RossoAL, RapoportAM, ScherAI. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache50(1) , 52–62 (2010).
  • Hedborg K , MuhrC. Multimodal behavioral treatment of migraine: an internet-administered, randomized, controlled trial. Ups. J. Med. Sci.116(3) , 169–186 (2011).
  • Lemstra M , StewartB, OlszynskiWP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache42(9) , 845–854 (2002).
  • Velati D , VianaM, CrestaS et al. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur. J. Pharmacol. 580(1–2) , 43–47 (2008).
  • Ho TW , FerrariMD, DodickDW et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372(9656) , 2115–2123 (2008).
  • Dodick DW , KostJ, AssaidC, LinesC, HoTW. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia31(3) , 296–300 (2011).
  • Ferrari MD , FärkkiläM, ReuterU et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia 30(10) , 1170–1178 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.